Fibrosoft
June 16, 2025
Company Presentation
Multiple Therapeutics
Fibrosoft: A novel non-surgical treatment of Dupuytren’s, Ledderhose’s and Peyronie’s- fibromatosis disease.
Introduction: The incidence of Dupuytren's disease over 65 years is 32-35%. This incidence is higher in European countries. Subcutaneous scarring and contracture affecting the hands (Dupuytren’s), feet (Ledderhose’s) are penis (Peyronie’s) are common. Conservatively, 28.8 million individuals have Dupuytren's contracture in the USA, UK and Australia alone. Higher in European countries. Approximately 1:10 men may have Peyronie’s disease. Surgery is the gold standard and recovery painful and arduous.
Solution: A novel nonsurgical intralesional injection. The formulation offers a safer and efficacious treatment of fibromatosis. Surgery in Ledderhose's disease worsens the condition.
Treatment: 270+ patients have been treated with 30% improvement following the first injection. Safe with no serious adverse events (SAES) observed. Over 90% of patients return for further injections.
Company HQ City:
Singapore
Company HQ State:
Singapore
Company HQ Country:
Singapore
Year Founded:
2024
Lead Product in Development:
Patients treated: 270+ patients have been treated with 30% improvement following the first injection. Safe with no serious adverse events (SAES) observed. Over 90% of patients return for further injections.
Competitor: There is currently no other known competitor or treatment option. The nearest competitor is (Endo) Xiaflex, based on non non-surgical approach, has high complication rates. Xiaflex, an enzyme, collagenase is injected into the affected areas and weakens the fibrotic scar. The physician manually straightens the finger to break the scar. This is often painful and has a high recurrence rate, tendon rupture, nerve injury and allergic reaction.
Our advantage : Non surgical option with no know complication and lower cost.
CEO
Dr. David Chin
Development Phase of Lead Product
Other/Not Applicable
Number of Unlicensed Products Looking for Licensing
Multi purpose use for - Dupuytren's, Ledderhose & Peyronie's disease-
When you expect your next catalyst update?
The inventor is seeking a licensee/VC funding to help exploit this attractive opportunity of over US$1.2B per annum. Australian and USA patents granted (Projected expiry date: 25th August 2042) and European application under early prosecution as shown below:-
•USA
•US Patent No. 12,280,095 on 22 April 2025.
•Europe
•European Application No. 22859663.1
•Under accelerated prosecution
•Australia
•Granted Australian Patent No. 2022335159
•Australian Divisional Application No. 2024200488
•Projected Expiry Date: 25 August 2042- (* Brisbane Olympic City 2032).
The 2015 acquisition of Auxilium Pharmaceuticals, Inc. by Endo International Plc (NASDAQ:ENDP, TSX:ENL) may be indicative of the potential of Fibrosoft, Of the amount paid to purchase all outstanding shares in the target, Endo apportioned US$2,619 million to intangible assets. Of this, US$1,501 million was allocated to Xiaflex®, approved for Duputren’s and Peyronie’s diseases, and US$90.9 million as Xiaflex® IPR&D for cellulite.
Net sales of Xiaflex® for the treatment of Peyronie’s disease and Dupuytren’s contracture for the eleven months from 29 January to 31 December 2015 were $158.1 million.
What is your next catalyst (value inflection) update?
Accelerated European patent IP: •European Application No. 22859663.1 to be completed end of the year (2025).
•Under accelerated prosecution.
Primary Speaker
Dr. David Chin MCh PhD(Plast) FRCS FRACS(Plast) Plastic Surgeon, Founder & CEO
Fibrosoft
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}